Literature DB >> 12382190

Molecular prognostic factors for breast cancer metastasis and survival.

Francisco J Esteva1, Aysegul A Sahin, Massimo Cristofanilli, Banu Arun, Gabriel N Hortobagyi.   

Abstract

The biological characteristics of the tumor are used to estimate prognosis and select appropriate systemic therapy for patients with early-stage breast cancer. Well-established molecular prognostic factors include the estrogen and progesterone receptors, proliferation markers, and the HER2 gene. Novel tumor markers with potential clinical utility include molecules involved in cell transformation, invasion, and metastases. We review the available data supporting the utility of established prognostic and predictive molecular factors, and discuss challenges for integrating novel molecular markers into clinical practice. Copyright 2002, Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12382190     DOI: 10.1053/srao.2002.35251

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  25 in total

Review 1.  Early breast cancer.

Authors:  Tomoyoshi Suzuki; Masakazu Toi; Shigehira Saji; Kazumi Horiguchi; Tomoyuki Aruga; Eiji Suzuki; Shinichiro Horiguchi; Nobuaki Funata; Katsuyuki Karasawa; Noriko Kamata
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.402

2.  Biomedical application of fuzzy association rules for identifying breast cancer biomarkers.

Authors:  F J Lopez; M Cuadros; C Cano; A Concha; A Blanco
Journal:  Med Biol Eng Comput       Date:  2012-05-24       Impact factor: 2.602

3.  Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer.

Authors:  Francisco J Esteva; Stacy L Moulder; Ana M Gonzalez-Angulo; Joe Ensor; James L Murray; Marjorie C Green; Kimberly B Koenig; Mong-Hong Lee; Gabriel N Hortobagyi; Sai-Ching Yeung
Journal:  Cancer Chemother Pharmacol       Date:  2012-09-28       Impact factor: 3.333

4.  Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.

Authors:  X He; F J Esteva; J Ensor; G N Hortobagyi; M-H Lee; S-C J Yeung
Journal:  Ann Oncol       Date:  2011-11-22       Impact factor: 32.976

Review 5.  Genome-based risk prediction for early stage breast cancer.

Authors:  Christina Adaniel; Komal Jhaveri; Adriana Heguy; Francisco J Esteva
Journal:  Oncologist       Date:  2014-09-03

Review 6.  Clinical utility of gene-expression signatures in early stage breast cancer.

Authors:  Maryann Kwa; Andreas Makris; Francisco J Esteva
Journal:  Nat Rev Clin Oncol       Date:  2017-05-31       Impact factor: 66.675

7.  Effect of HER2 status on distant recurrence in early stage breast cancer.

Authors:  Kenneth R Hess; Francisco J Esteva
Journal:  Breast Cancer Res Treat       Date:  2012-12-06       Impact factor: 4.872

8.  PPARgamma and Wnt/beta-Catenin pathway in human breast cancer: expression pattern, molecular interaction and clinical/prognostic correlations.

Authors:  Ying Jiang; Lin Zou; Chunhui Zhang; Song He; Chun Cheng; Junfei Xu; Weiqi Lu; Yong Zhang; Hua Zhang; Donglin Wang; Aiguo Shen
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-03       Impact factor: 4.553

9.  Time-varying effects of prognostic factors associated with disease-free survival in breast cancer.

Authors:  Loki Natarajan; Minya Pu; Barbara A Parker; Cynthia A Thomson; Bette J Caan; Shirley W Flatt; Lisa Madlensky; Richard A Hajek; Wael K Al-Delaimy; Nazmus Saquib; Ellen B Gold; John P Pierce
Journal:  Am J Epidemiol       Date:  2009-04-29       Impact factor: 4.897

10.  Human endogenous retrovirus type K antibodies and mRNA as serum biomarkers of early-stage breast cancer.

Authors:  Feng Wang-Johanning; Ming Li; Francisco J Esteva; Kenneth R Hess; Bingnan Yin; Kiera Rycaj; Joshua B Plummer; Jeremy G Garza; Stefan Ambs; Gary L Johanning
Journal:  Int J Cancer       Date:  2013-09-13       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.